Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model

Yu LIU; Xing WANG; Zi-Ying CHEN; Wen-Li ZHANG; Lin GUO; Yong-Quan SUN; Hong-Zhan CUI; Ji-Qiang BU; Jian-Hui CAI

doi:10.11909/j.issn.1671-5411.2021.06.006

Volume 18 Issue 6

Jun. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2021 > 18(6): 449-461

Please cite this article as: LIU Y, WANG X, CHEN ZY, ZHANG WL, GUO L, SUN YQ, CUI HZ, BU JQ, CAI JH. Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model. J Geriatr Cardiol 2021; 18(6): 449−461. DOI: 10.11909/j.issn.1671-5411.2021.06.006

Citation:

Please cite this article as: LIU Y, WANG X, CHEN ZY, ZHANG WL, GUO L, SUN YQ, CUI HZ, BU JQ, CAI JH. Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model. J Geriatr Cardiol 2021; 18(6): 449−461. DOI: 10.11909/j.issn.1671-5411.2021.06.006

Citation:

PDF( 4994 KB)

Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model

doi: 10.11909/j.issn.1671-5411.2021.06.006

1.
Department of Surgery, Hebei Medical University, Shijiazhuang, China
2.
Department of Cardiac Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, China
3.
Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang, China
4.
School of Industrial and Systems Engineering, University of Oklahoma, Norman, USA
5.
Department of Surgery and Oncology, Hebei General Hospital, Shijiazhuang, China

More Information

Corresponding author: drcrpauthor@163.com
Available Online: 2021-05-28
Publish Date: 2021-06-22

Abstract

Abstract

BACKGROUND Severe bleeding following cardiac surgery remains a troublesome complication, but to date, there is a lack of comprehensive predictive models for the risk of severe bleeding following off-pump coronary artery bypass grafting (OPCABG). This study aims to analyze relevant indicators of severe bleeding after isolated OPCABG and establish a corresponding risk assessment model. METHODS The clinical data of 584 patients who underwent OPCABG from January 2018 to April 2020 were retrospectively analyzed. We gathered the preoperative baseline data and postoperative data immediately after intensive care unit admission and used multifactor logistic regression to screen the potential predictors of severe bleeding, upon which we established a predictive model. Using the consistency index and calibration curve, decision curve, and clinical impact curve analysis, we evaluated the performance of the model. RESULTS This study is the first to establish a risk assessment and prediction model for severe bleeding following isolated OPCABG. Eight independent risk factors were identified: male sex, aspirin/clopidogrel withdrawal time, platelet count, fibrinogen level, C-reactive protein, serum creatinine, and total bilirubin. Among the 483 patients in the training group, 138 patients (28.6%) had severe bleeding; among the 101 patients in the verification group, 25 patients (24.8%) had severe bleeding. Receiver operating characteristic (ROC) curve analysis for the internal training group revealed a convincing performance with a concordance index (C-index) of 0.859, while the area under the ROC curve for the external validation data was 0.807. Decision curve analysis showed that the model was useful for both groups. CONCLUSIONS Although there are some limitations, the model can effectively predict the probability of severe bleeding following isolated OPCABG and is therefore worthy of further exploration and verification.

FullText(HTML)

References(56)

References

[1]	Expert consensus group on the revascularization of coronary heart disease in China. [Revascularization of coronary heart disease expert consensus in China]. Chin J Thorac Cardiovasc Surg 2016; 32: 707−716. [In Chinese]. doi: 10.3760/cma.j.issn.1001-4497.2016.12.002
[2]	Ucar HI, Oc M, Tok M, et al. Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. Heart Surg Forum 2007; 10: E392−E396. doi: 10.1532/HSF98.20071065
[3]	Welsby IJ, Jiao K, Ortel TL, et al. The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20: 531−535. doi: 10.1053/j.jvca.2005.04.013
[4]	Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91: 944−982. doi: 10.1016/j.athoracsur.2010.11.078
[5]	Besser MW, Klein AA. The coagulopathy of cardiopulmonary bypass. Crit Rev Clin Lab Sci 2010; 47: 197−212. doi: 10.3109/10408363.2010.549291
[6]	Despotis G, Eby C, Lublin DM, et al. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008; 48: 2S−30S. doi: 10.1111/j.1537-2995.2007.01573.x
[7]	Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693−1701. doi: 10.1016/j.jacc.2008.08.031
[8]	Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267−281. doi: 10.1177/108925320400800402
[9]	Moulton MJ, Creswell LL, Mackey ME, et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037−1046. doi: 10.1016/S0022-5223(96)70380-X
[10]	Liu X, Zhang W, Chen N, et al. Can preoperative C-reactive protein predict bleeding after on-pump coronary artery bypass grafting? Ann Thorac Surg 2020; 109: 541−546. doi: 10.1016/j.athoracsur.2019.06.059
[11]	Leong JY, Baker RA, Shah PJ, et al. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005; 80: 928−933. doi: 10.1016/j.athoracsur.2005.03.074
[12]	Paparella D, Brister SJ, Buchanan MR, et al. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873−1881. doi: 10.1007/s00134-004-2388-0
[13]	Hall TS, Sines JC, Spotnitz AJ, et al. Hemorrhage related reexploration following open heart surgery: the impact of pre-operative and post-operative coagulation testing. Cardiovasc Surg 2002; 10: 146−153. doi: 10.1016/S0967-2109(01)00129-6
[14]	Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994; 58: 216−221. doi: 10.1016/0003-4975(94)91103-7
[15]	Gherli R, Mariscalco G, Dalén M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016; 1: 921−928. doi: 10.1001/jamacardio.2016.3028
[16]	Fink N, Nikolsky E, Assali A, et al. Revascularization strategies and survival in patients with multivessel coronary artery disease. Ann Thorac Surg 2019; 107: 106−111. doi: 10.1016/j.athoracsur.2018.07.070
[17]	Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71−86. doi: 10.1136/bmj.324.7329.71
[18]	Khan SU, Talluri S, Rahman H, et al. Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting. Eur J Prev Cardiol 2019; 26: 215−218. doi: 10.1177/2047487318788613
[19]	Hesterberg K, Rawal A, Khan S, et al. A meta-analysis comparing aspirin alone versus dual antiplatelet therapy for the prevention of venous graft failure following coronary artery bypass surgery. Cardiovasc Revasc Med 2020; 21: 792−796. doi: 10.1016/j.carrev.2019.10.022
[20]	Solo K, Lavi S, Kabali C, et al. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ 2019; 367: l5476. doi: 10.1136/bmj.l5476
[21]	Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 2010; 56: 1639−1643. doi: 10.1016/j.jacc.2010.03.104
[22]	Martin AC, Berndt C, Calmette L, et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol 2016; 33: 361−367. doi: 10.1097/EJA.0000000000000348
[23]	Hansson EC, Shams Hakimi C, Åström-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014; 112: 570−575. doi: 10.1093/bja/aet339
[24]	Pagano D, Milojevic M, Meesters MI, et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53: 79−111. doi: 10.1093/ejcts/ezx325
[25]	Myles PS, Smith JA, Forbes A, et al. Stopping versus continuing aspirin before coronary artery surgery. N Engl J Med 2016; 374: 728−737. doi: 10.1056/NEJMoa1507688
[26]	Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a systematic review and meta-analysis. Br J Anaesth 2015; 115: 376−385. doi: 10.1093/bja/aev164
[27]	Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309−1317. doi: 10.1056/NEJMoa020798
[28]	Chu MW, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004; 78: 1536−1541. doi: 10.1016/j.athoracsur.2004.03.028
[29]	CABG Perioperation Antiplatelet Therapy Expert Group. [Expert cosensus statement on antiplatelet therapy in CABG perioperation]. Chin J Thorac Cardiovasc Surg 2016; 32: 1−8. [In Chinese]. doi: 10.3760/cma.j.issn.1001-4497.2016.01.001
[30]	Zghaibe W, Scheuermann S, Munting K, et al. Clinical utility of the Quantra® point-of-care haemostasis analyser during urgent cardiac surgery. Anaesthesia 2020; 75: 366−373. doi: 10.1111/anae.14942
[31]	Bosch Y, Al Dieri R, ten Cate H, et al. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. J Cardiothorac Surg 2013; 8: 154. doi: 10.1186/1749-8090-8-154
[32]	Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101−1107. doi: 10.1160/TH04-12-0799
[33]	Ranucci M, Jeppsson A, Baryshnikova E, et al. Pre-operative fibrinogen supplementation in cardiac surgery patients: an evaluation of different trigger values. Acta Anaesthesiol Scand 2015; 59: 427−433. doi: 10.1111/aas.12469
[34]	Gielen C, Dekkers O, Stijnen T, et al. The effects of pre- and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2014; 18: 292−298. doi: 10.1093/icvts/ivt506
[35]	Bolliger D, Görlinger K, Tanaka KA, et al. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113: 1205−1219. doi: 10.1097/ALN.0b013e3181f22b5a
[36]	Karlsson M, Ternström L, Hyllner M, et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008; 48: 2152−2158. doi: 10.1111/j.1537-2995.2008.01827.x
[37]	Karkouti K, Callum J, Crowther MA, et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg 2013; 117: 14−22. doi: 10.1213/ANE.0b013e318292efa4
[38]	Tanaka KA, Esper S, Bolliger D, et al. Perioperative factor concentrate therapy. Br J Anaesth 2013; 111: i35−i49. doi: 10.1093/bja/aet380
[39]	Yanagawa B, Ribeiro R, Lee J, et al. Platelet transfusion in cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg 2021; 111: 607−614. doi: 10.1016/j.athoracsur.2020.04.139
[40]	Dias JD, Sauaia A, Achneck HE, et al. Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: a systematic review and analysis. J Thromb Haemost 2019; 17: 984−994. doi: 10.1111/jth.14447
[41]	Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2016; 152: 1243−1275. doi: 10.1016/j.jtcvs.2016.07.044
[42]	Lopes CT, Dos Santos TR, Brunori EH, et al. Excessive bleeding predictors after cardiac surgery in adults: integrative review. J Clin Nurs 2015; 24: 3046−3062. doi: 10.1111/jocn.12936
[43]	Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544−2565. doi: 10.1161/CIRCULATIONAHA.107.188965
[44]	Strilchuk L, Besh D. Estimation of cardiosurgical intervention risk according to EuroSCORE in patients with acute coronary syndrome and different gallbladder conditions before coronary artery bypass grafting. Kardiochir Torakochirurgia Pol 2018; 15: 238−240. doi: 10.5114/kitp.2018.80920
[45]	Patel K, Adalti S, Runwal S, et al. Re-exploration after off-pump coronary artery bypass grafting: incidence, risk factors, and impact of timing. J Card Surg 2020; 35: 3062−3069. doi: 10.1111/jocs.14986
[46]	Sharma P, Ananthanarayanan C, Vaidhya N, et al. Hyperbilirubinemia after cardiac surgery: an observational study. Asian Cardiovasc Thorac Ann 2015; 23: 1039−1043. doi: 10.1177/0218492315607149
[47]	Nishi H, Sakaguchi T, Miyagawa S, et al. Frequency, risk factors and prognosis of postoperative hyperbilirubinemia after heart valve surgery. Cardiology 2012; 122: 12−19. doi: 10.1159/000338142
[48]	Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014; 29: 29−40. doi: 10.1093/ndt/gft209
[49]	Gunertem E, Urcun S, Pala AA, et al. Predictiveness of different preoperative risk assessments for postoperative bleeding after coronary artery bypass grafting surgery. Perfusion 2021; 36: 277−284. doi: 10.1177/0267659120941327
[50]	Göbel K, Eichler S, Wiendl H, et al. The coagulation factors fibrinogen, thrombin, and factor xii in inflammatory disorders: a systematic review. Front Immunol 2018; 9: 1731. doi: 10.3389/fimmu.2018.01731
[51]	Eapen DJ, Manocha P, Patel RS, et al. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol 2013; 62: 329−337. doi: 10.1016/j.jacc.2013.03.072
[52]	Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310−1320. doi: 10.1056/NEJMoa1107477
[53]	O’Brien M. The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med 2012; 27: 46−52. doi: 10.1053/j.tcam.2012.06.003
[54]	Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417−430. doi: 10.1111/j.1365-2141.2005.05753.x
[55]	Ji Y, Fish PM, Strawn TL, et al. C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts. J Thromb Haemost 2014; 12: 1667−1677. doi: 10.1111/jth.12680
[56]	Wu J, Stevenson MJ, Brown JM, et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 2008; 28: 698−704. doi: 10.1161/ATVBAHA.107.160903